AxisPharm provides high purity PROTAC PEG reagents (linkers) with various active groups, such as azide, acid, amine, etc.
The design of Proteolysis Targeting Chimera (PROTACs) is a powerful small molecule approach for inducing protein degradation for anticancer therapy. PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker. To further empower the PROTAC study, AxisPharm are developing a series of PROTAC linker to accelerate our customers’ R&D effort.
![l-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-lHpyrazolo [3,4-d]pyrimidin-l-yl]-l-piperidinyl]-2-propyn-l-one](https://axispharm.com/wp-content/uploads/AP14272.png)
![N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine](https://axispharm.com/wp-content/uploads/AP14270.png)
![3-{5,7-dioxo-5H,6H,7H-pyrrolo[3,4-b]pyridin-6-yl}piperidine-2,6-dione](https://axispharm.com/wp-content/uploads/AP13955-1.png)
